(CYTR, SAPX, PCRX) CRWENewswire Stocks in Action
- Uploaded by Karmastock on Oct 31, 2011
- Views: 193
Good Monday Morning, Its October 31st, 2011, Iâ€™m Lynn Lumpkin with CRWENewswire Stocks In Action. CytRx Corporation - symbol CYTR - announced favorable response and safety indications from a group of patients with advanced solid tumors in the Companyâ€™s ongoing Phase 1b/2 clinical trial with INNO-206, its tumor-targeting conjugate of the commonly used chemotherapeutic agent doxorubicin. For the fiscal year ended June 30, 2011, Seven Arts Pictures plc, the NASDAQ listing predecessor of Seven Arts Entertainment Inc. - symbol SAPX - today reported revenue of $3,328,000 and net income of $1,462,000, representing $0.77 of basic and diluted earnings per share and finally, Pacira Pharmaceuticals, Inc. - symbol PCRX - announced financial results for the third quarter ended September 30, 2011 and provided an update on the U.S. Food and Drug Administration's approval of EXPARELâ„¢ and the commercial strategy to support the product launch. Pacira reiterated its revenue expectations for 2011, they currently expect to achieve revenue in the range of $14 to $16 million for the full-year ending December 31, 2011 and this revenue expectation excludes the impact of potential sales of EXPAREL. EXPAREL is an innovative product that combines bupivacaine with DepoFoamÂ®, a proven product delivery technology that delivers medication over a desired time period. Thanks for joining me and have a great monday! For CRWE Newswire, Stocks In Action, Iâ€™m Lynn Lumpkin.